Home

news002

FDA Requests More Information on Certriad

LONDON (AP) - AstraZeneca PLC and Abbott Laboratories said that the U.S. Food and Drug Administration has asked for more information about their Certriad cholesterol drug before approving it for sale.

The companies said that FDA has sought more data in a so-called complete response letter (CRL) to their new drug application, which combines their cholesterol pills TriLipix and Crestor.

Abbott's TriLipix is part of a class of drugs called fibrates that raise "good" HDL cholesterol while reducing triglycerides and "bad" LDL cholesterol. AstraZeneca's Crestor is a statin drug that lowers bad cholesterol while raising good cholesterol.

Studies conducted by the companies compared the combination pill versus separate treatment with statin and fibrate drugs.

The companies' application to the FDA seeks approval to treat dyslipidemia, a disorder characterized by elevated cholesterol and triglycerides, a type of fat found in the blood stream. More than 100 million adults in the U.S. have the disorder, according to the American Heart Association.

The companies said they will continue discussions with the FDA to "determine the next steps," while responding to the request for more information.

Source: Associated Press

News & Events

  • Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>